Hybridoma technology has been a cornerstone of monoclonal antibody production for decades, enabling researchers to generate continuous supplies of antibodies with defined antigen specificity. Since its introduction in 1975, the technique has supported advances in biomedical research, diagnostics, and therapeutic development.
Although newer antibody discovery technologies have emerged, hybridoma generation remains an established approach for obtaining monoclonal antibodies. Understanding its workflow, from immunization and cell fusion to screening and sequencing, is important for selecting reliable antibody-producing clones and supporting downstream applications.
Hybridoma generation is a technique that combines antibody-producing B lymphocytes with immortal myeloma cells to create hybrid cell lines capable of sustained antibody secretion.
Developed by Georges Köhler and César Milstein in 1975, the method addressed a fundamental limitation in antibody production. Normal antibody-producing B cells have limited lifespans in culture, making it difficult to maintain a continuous supply of a specific antibody. Myeloma cells, by contrast, can proliferate indefinitely but are selected so that they do not produce interfering immunoglobulins.
By fusing these two cell types, researchers generate hybridomas that combine the antibody-producing capability of B cells with the long-term growth properties of myeloma cells.
After screening and cloning, a selected hybridoma can be expanded and maintained as a source of monoclonal antibodies for research, diagnostic, or therapeutic development.
Despite advances in phage display, single B cell screening, and computational antibody design, hybridoma technology remains useful because of its established methodology and ability to produce antibodies from selected cell clones.
Once a suitable hybridoma has been isolated and stabilized, it can be expanded to produce repeated batches of the same antibody. This is particularly valuable for applications that require consistent antibody reagents over extended periods.
Hybridoma-derived antibodies have supported applications ranging from immunoassays and protein characterization to the development of therapeutic antibody candidates.1
Hybridoma generation involves several stages, each influencing the diversity, specificity, and quality of the antibodies ultimately recovered.
The process begins by immunizing an animal, commonly a mouse, with the antigen of interest to stimulate an immune response.
The antigen's structure, purity, and presentation can influence the specificity and diversity of the antibodies generated. Immunization schedules typically include multiple administrations over several weeks to promote B cell activation and antibody production.
Serum antibody titers may be evaluated using ELISA or other binding assays before proceeding with cell isolation.
Following immunization, antibody-producing B cells are collected from lymphoid tissues, most commonly the spleen.
These cells contain the genetic information encoding antibodies generated during the immune response. However, they cannot typically be maintained indefinitely under standard culture conditions.
To preserve their antibody-producing capabilities, the isolated cells are fused with immortal myeloma cells.
B cells and myeloma cells are combined using a fusion method such as polyethylene glycol (PEG)-mediated fusion or electrofusion.
The resulting population contains successfully fused hybridomas, unfused parental cells, and other fusion products. A selection step is therefore required to isolate the desired cells.
This is commonly achieved using hypoxanthine-aminopterin-thymidine (HAT) medium.
Aminopterin blocks de novo nucleotide synthesis, forcing cells to rely on the nucleotide salvage pathway. The selected myeloma fusion partner lacks the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT), preventing unfused myeloma cells from surviving under these conditions.
Hybridomas, however, inherit functional salvage-pathway machinery from their B cell parent and the capacity for continued proliferation from the myeloma cell.
Unfused B cells eventually die because of their limited lifespan, leaving surviving hybridomas available for screening.
Following selection, hybridoma culture supernatants are screened to identify clones secreting antibodies that recognize the intended antigen.
ELISA is commonly used for initial screening, although flow cytometry, cell-based assays, and other methods may be more appropriate for certain targets.
The screening strategy is especially important when antibodies must recognize native protein conformations or cell-surface antigens.
For example, an antibody that binds a purified recombinant protein in ELISA may not necessarily recognize the same antigen in its native cellular environment.
Combining initial binding assays with application-specific confirmation helps identify candidates with properties relevant to their intended use.
Once promising hybridomas have been identified, they undergo subcloning to establish monoclonal cell populations.
Limiting dilution is one commonly used approach, in which cells are distributed at low density to increase the likelihood of obtaining colonies derived from individual cells. Because limiting dilution does not always establish monoclonality conclusively, additional rounds of cloning or appropriate single-cell documentation may be necessary.
Selected clones are expanded, characterized, and cryopreserved to maintain a long-term source of antibody-producing cells.
Established hybridomas can be cultured to produce monoclonal antibodies, which are subsequently collected from culture supernatants and purified.
The resulting antibodies are characterized according to their intended applications. Common assessments include antigen-binding specificity, isotype identification, affinity measurements, and functional assays.
For antibodies intended for further development, identifying the underlying heavy- and light-chain sequences provides another important layer of characterization.
Hybridoma technology offers several advantages, but it also introduces technical and biological challenges that can affect antibody discovery and long-term production.
| Advantages | Limitations |
|---|---|
| Established monoclonal antibody discovery method | Cell fusion and selection can be inefficient |
| Supports sustained antibody production from stable clones | Hybridoma cell lines may lose productivity or stability |
| Enables screening of antibodies generated through an immune response | Some antibody-producing B cells are lost during the workflow |
| Selected clones can be expanded and cryopreserved | Continued production depends on maintaining viable cell lines |
| Well-established laboratory procedures | Antibody sequence information is not automatically obtained |
Mitra and Tomar (2021) describe fusion efficiency, extended development timelines, and cell culture contamination as challenges associated with hybridoma technology.1
These limitations become especially relevant when a hybridoma produces an antibody with valuable binding or functional properties. Losing the cell line through contamination, genetic instability, or improper storage could compromise access to the antibody.
For this reason, modern hybridoma workflows increasingly benefit from strategies that preserve not only the producing cells but also the antibody's molecular identity.
A hybridoma cell line provides a biological source of a monoclonal antibody, but the cell line itself does not reveal the exact amino acid sequence of the antibody it produces.
Hybridoma sequencing addresses this gap by identifying the nucleotide sequences encoding the antibody's variable heavy (VH) and variable light (VL) regions.
These regions contain the complementarity-determining regions (CDRs), which contribute directly to antigen recognition.
Knowing the antibody sequence provides several advantages:
Preserving antibody identity: Sequence information creates a molecular record of a valuable antibody, reducing dependence on continued maintenance of the original hybridoma.
Enabling recombinant production: Once the relevant heavy- and light-chain sequences are identified, they can be incorporated into expression constructs for antibody production in recombinant systems.
Supporting antibody engineering: Sequence information provides the basis for humanization, affinity maturation, and modification of antibody formats.
Supporting molecular characterization: Antibody sequences can help distinguish individual clones and provide information for sequence documentation and intellectual property assessment.
One established approach for recovering antibody variable-region sequences is 5′ rapid amplification of cDNA ends (5′ RACE). This technique uses RNA extracted from hybridoma cells to generate complementary DNA and amplify antibody transcripts for sequencing.
Although sequencing establishes the molecular identity of the expressed antibody chains, experimental validation remains important. Recombinant antibodies should be tested to confirm that their binding and functional properties are consistent with those of the original hybridoma-derived antibody.
Once the relevant antibody sequences have been recovered, researchers can move from cell line-dependent production toward recombinant expression.
The identified VH and VL sequences can be cloned into expression vectors containing the appropriate constant regions and introduced into mammalian expression systems, such as HEK293 or CHO cells.
This makes it possible to produce the antibody without relying on continued culture of the original hybridoma.
Recombinant expression also creates opportunities to modify antibody formats. For example, researchers may retain the original variable regions while changing the constant region to produce a different antibody isotype.
Similarly, sequence information can support antibody engineering approaches intended to improve affinity, reduce immunogenicity, or modify other molecular properties.
For laboratories maintaining valuable hybridoma collections, sequence recovery can therefore serve both as a preservation strategy and as a starting point for further antibody development.
Biointron's Hybridoma Sequencing service supports this transition by recovering antibody variable-region sequences using 5′ RACE.
The service includes sequencing and cross-verification of at least five independent clones, with sequence results typically delivered within one week of sample receipt. Researchers can also pursue downstream recombinant antibody expression and purification.
A successful hybridoma project requires more than identifying an antibody-producing clone. Long-term reliability depends on screening quality, cell line management, and appropriate molecular characterization.
Several practices can help reduce downstream risks:
Use application-relevant screening assays. Confirm that selected antibodies recognize their targets under conditions relevant to their intended use.
Establish and verify monoclonality. Ensure selected hybridoma populations originate from individual antibody-producing cells.
Monitor antibody production. Periodically assess secretion and binding activity to detect changes during cell culture.
Cryopreserve valuable clones. Maintain appropriately documented backup stocks to reduce the risk of losing important cell lines.
Recover antibody sequences. Consider sequencing promising hybridomas early to preserve molecular information for recombinant expression and future engineering.
Integrating these practices helps improve reproducibility while allowing valuable antibody candidates to remain accessible as research programs evolve.
What is the purpose of hybridoma generation?
Hybridoma generation creates immortalized cell lines capable of producing monoclonal antibodies with defined antigen specificity. These cells are obtained by fusing antibody-producing B lymphocytes with myeloma cells.
How are hybridoma cells selected after fusion?
Hybridomas are commonly selected using HAT medium. Under these conditions, unfused myeloma cells cannot survive because they lack a functional nucleotide salvage pathway, while unfused B cells have limited lifespans. Successfully fused hybridomas can continue proliferating.
How are antigen-specific hybridomas identified?
Hybridoma culture supernatants are screened using assays such as ELISA, flow cytometry, or cell-based binding assays. Additional characterization may be needed to confirm specificity, affinity, and functional activity.
Can hybridoma cells lose antibody production over time?
Yes. Hybridoma cell lines may experience genetic or phenotypic changes that affect antibody expression. Regular monitoring, cryopreservation, and sequence documentation can help reduce associated risks.
Why is hybridoma sequencing important?
Hybridoma sequencing identifies the VH and VL sequences encoding a monoclonal antibody. This information supports recombinant antibody production, sequence documentation, humanization, and affinity maturation.
Can a hybridoma-derived antibody be produced recombinantly?
Yes. Once the appropriate heavy- and light-chain sequences have been recovered, they can be cloned into recombinant expression vectors and expressed in suitable host cells. The resulting antibody should be characterized to confirm its properties.
Hybridoma generation remains an important approach to monoclonal antibody discovery, offering an established method for selecting and producing antibodies against specific targets.
However, maintaining stable cell lines and preserving antibody identity are important considerations for long-term research and development.
Combining hybridoma technology with antibody sequencing allows researchers to retain the molecular information underlying valuable antibody candidates while enabling recombinant production and further engineering.
Biointron's Hybridoma Sequencing service supports this process through full-length variable-region sequencing, sequence verification, and optional downstream recombinant antibody production.
Mitra, S., & Tomar, P. C. (2021). Hybridoma technology; advancements, clinical significance, and future aspects. Journal of Genetic Engineering and Biotechnology, 19, 159. https://doi.org/10.1186/s43141-021-00264-6
Köhler, G., & Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256, 495–497. https://doi.org/10.1038/256495a0
Artificial intelligence (AI) is changing how therapeutic antibodies are discover……
Biointron announces limited-time RushData launch pricing for high-throughput ant……
Learn how direct antigen labeling improves single B cell antibody screening by r……
You can also contact us on the Scientist and Science Exchange marketplaces.